CDX-1140

Phase 2Small molecule

CCelldex Therapeutics

CDX-1140 is one of 52 small molecule programs targeting T Cells. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

T CellsActive, not recruiting

Breast CancerRecruiting

Biliary Tract CarcinomaRecruiting

T CellsPhase 1

Active, not recruiting

Breast CancerPhase 1

Recruiting

Biliary Tract CarcinomaPhase 2

Recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Lexiscan

Astellas

Preclinical

1 2

Voltaren

Novartis

Preclinical

1 3

CDX-1140

CCelldex Therapeutics

Phase 2

1 4

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 5

Tricor

JJagotec

Preclinical

1 6

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 7

Tianeptine

Pfizer

Preclinical

1 8

Ablavar

LLantheus Medical Imaging

Preclinical

2 9

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 10

Naltrexone/bupropion

Novo Nordisk

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

T Cells

NCT04520711

Q2 2028

Phase 1Active, not recruiting

T Cells

NCT05349890

Q2 2042

Phase 1/2Recruiting

Biliary Tract Carcinoma

NCT05849480

Clinical

Trials by Indication[1]

T Cells2 trials

Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

Active, not recruiting·PProvidence Health & Services·Phase 1·NCT05349890·1 enrolled

Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

Active, not recruiting·PProvidence Health & Services·Phase 1·NCT04520711·24 enrolled

Breast Cancer1 trial

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 1·NCT05029999·30 enrolled

Biliary Tract Carcinoma1 trial

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

Recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT05849480·60 enrolled

Advanced Malignancies1 trial

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Completed·CCelldex Therapeutics·Phase 1·NCT03329950·132 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Terminated·HHiberCell, Inc.·Phase 1·NCT05484011·5 enrolled

2 more indications

Pancreatic Cancer1 trial

Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients

Terminated·WWashington University School of Medicine·Phase 2·NCT04536077·16 enrolled

Ocular Melanoma1 trial

Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)

Completed·CCraig L Slingluff, Jr·Phase 1/2·NCT04364230·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for CDX-1140. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CDX-1140 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CDX-1140. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Celldex Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCelldex Therapeutics

CDX-1140

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2028

Q2 2042

Trials by Indication[1]

T Cells2 trials

Breast Cancer1 trial

Biliary Tract Carcinoma1 trial

Advanced Malignancies1 trial

Pancreatic Ductal Adenocarcinoma1 trial

Pancreatic Cancer1 trial

Ocular Melanoma1 trial

References

Drug Info

Quick Facts

Related News